Oncology

Early clinical results reveal that the novel KRAS G12D inhibitor GFH375 achieves a 41% response rate and 97% disease control in advanced…

The DESTINY-Breast11 phase 3 trial presented at ESMO 2025 revealed that the anthracycline-free neoadjuvant T-DXd-THP regimen achieved a 67.3% pathologic complete response rate.

A risk-stratified approach significantly enhanced skin cancer detection after organ transplantation without increasing health care burden.

Statin use linked to better survival but higher cardiac adverse events in advanced prostate cancer patients treated with apalutamide, according to recent analysis.

Study reveals how TP53 mutations alter lung adenocarcinoma tumour microenvironment, influencing progression and immunotherapy response.

New study reveals how iron levels influence FLASH radiotherapy’s dual effect of tumour control and normal tissue protection.

A longitudinal study of 188 cervical cancer patients undergoing brachytherapy revealed that multidimensional fatigue slightly increased during treatment, peaking after five sessions, then significantly decreased one month post-treatment.

A new study reveals circulating tumour DNA correlates with tumour volume in metastatic pancreatic cancer, particularly with liver metastases.